David Pyott, CBE
BioMarin Pharmaceutical – Board Member
Alnylam Pharmaceutical – Board Member
Philips – Board Member
Avery Dennison – Board Member
During his 17 year tenure, Allergan was transformed from a small eye care business with about $1 billion in sales to a global specialty pharmaceutical and medical device company, with sales over $7 billion in 2014. Mr. Pyott was recognized by Harvard Business Review as one of “The 100 Best Performing CEOs in the World” in 2014 (ranked #4).
Allergan has been the fastest growing global ophthalmic company for many years and is globally #1 or #2 multiple specialty areas: ophthalmics, medical aesthetics, medical dermatology, neurology, and urologics. The company’s strategy was based on customer focus, investment in R&D, creation of new markets and commercial prioritization of high growth products. As an innovator with a strong background in consumer marketing, Mr. Pyott recognized the potential of BOTOX® to be used for cosmetic and therapeutic purposes. Allergan’s investment in Research & Development increased from less than $100 million in 1998 to over $1 billion in 2014, with the company creating an industry-leading Research & Development pipeline.
In 2006, Mr. Pyott was bestowed with the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen in acknowledgement of his contribution to British business excellence and management skills in the United States. In 2010, he received an honorary degree, the UCI Medal, the Moacyr Gold Medal for services to Brazilian ophthalmology, and in 2013 the Semper Fidelis Award from the US Marine Corps.
Before Allergan, Mr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of the Switzerland-based Novartis AG, having worked 17 years in Switzerland, Austria, Spain, Malaysia and the United States.
Mr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree from the University of Edinburgh and a Master of Business Administration degree from the London Business School.
Mr. Pyott is Lead Director and a member of the Board of Directors of Avery Dennison Corporation, a member of the Board of Alnylam Pharmaceuticals Inc., BioMarin Pharmaceutical Inc. and a member of the Supervisory Board of Royal Philips in the Netherlands. He is a member of the Board of Trustees of Chapman University, a member of the Governing Board of the London Business School, President of the International Council of Ophthalmology Foundation and is on the Advisory Board of the Foundation of the American Academy of Ophthalmology. He formerly served on the Board, on the Executive Committee and as Board Secretary of the Biotechnology Industry Organization as well as on the Board of Edwards Lifesciences Corporation.